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Background: Radioguided surgery using 99m-Technetium-methoxyisobutylisonitrile (99mTc-MIBI) has been
recommended for the surgical treatment of mediastinal parathyroid adenomas. However, high myocardial
99mTc-MIBI uptake may limit the feasibility of radioguided surgery in aortopulmonary window parathyroid adenoma.
Case presentation: Two female patients aged 72 (#1) and 79 years (#2) with primary hyperparathyroidism caused
by parathyroid adenomas in the aortopulmonary window were operated by transsternal radioguided surgery. After
intravenous injection of 370 MBq 99mTc-MIBI at start of surgery, the maximum radioactive intensity (as counts per
second) was measured over several body regions using a gamma probe before and after removal of the
parathyroid adenoma. Relative radioactivity was calculated in relation to the measured ex vivo radioactivity of the
adenoma, which was set to 1.0.
Both patients were cured by uneventful removal of aortopulmonary window parathyroid adenomas of 4400 (#1)
and 985 mg (#2). Biochemical cure was documented by intraoperative measurement of parathyroid hormone as
well as follow-up examination. Ex vivo radioactivity over the parathyroid adenomas was 196 (#1) and 855 counts
per second (#2). Before parathyroidectomy, relative radioactivity over the aortopulmonary window versus the heart
was found at 1.3 versus 2.6 (#1) and 1.8 versus 4.8 (#2). After removal of the adenomas, radioactivity within the
aortopulmonary window was only slightly reduced.
Conclusion: High myocardial uptake of 99mTc-MIBI limits the feasibility of radioguided surgery in aortopulmonary
parathyroid adenoma.
Keywords: 99mTc-MIBI scintigraphy, Aortopulmonary window parathyroid adenoma, Radioguided surgery, Primary
hyperparathyroidismBackground
Radioguided surgery (RGS) using the radioactive tracer
99m-Technetium-methoxyisobutylisonitrile (99mTc-MIBI)
has been recommended for treating patients with primary
hyperparathyroidism (PHPT), in particular in recurrent
disease and atypical localization of the parathyroid glands
(e.g. in the mediastinum) [1-4]. Potential benefits of RGS
are (a) better identification of pathological parathyroid tis-
sue by intraoperative detection of regions with highest
tracer uptake and (b) control of cure by comparison of the* Correspondence: thomas.schwarzlmueller@gmail.com
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article, unless otherwise stated.ex vivo radioactivity over the removed tissue and in vivo
activity within the resection area [5-7].
The main prerogative of this method is the selective
(or higher) uptake of the tracer in parathyroid tissue when
compared to the surrounding tissue [8-10]. 99mTc-MIBI, a
tracer that was originally developed for myocardial scintig-
raphy, has however physiological uptake in the myocar-
dium as well as uptake in many thyroid nodules including
thyroid cancer [9,11]. For reliable discrimination in cer-
vical PHPT surgery, a ratio between thyroid tissue and
parathyroid adenoma of at least 1:1.3-1.5 has been sug-
gested [4,12,13]. After removal of the parathyroid aden-
oma, an ex vivo radioactivity counting rate over the
adenoma of more than 20% compared to the thyroidCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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to be a credible criterion for successful excision [13].
Several studies have been published concerning a benefit
for RGS in intraoperative identification of mediastinal para-
thyroid adenomas [5,15-17]. The majority of mediastinal
parathyroid adenomas are localized in the thymus, the an-
terior superior mediastinum, or the tracheo-oesophageal
groove in the upper mediastinum [6,16,18].
In less than 1 of 1,000 patients, however, parathyroid ad-
enomas can be found in the aortopulmonary window
(APW), which is localized deeper and more posterior in the
mediastinum between the aorta and the left pulmonary ar-
tery, in the region of the tracheal bifurcation and near to
the heart [15,19,20]. In APW parathyroid adenomas RGS
has been tested in only a few cases [20]. In contrast to the
neck, no standard protocol has so far been established for
RGS in APW parathyroid adenomas [2]. In particular, the
high myocardial MIBI uptake may be a limiting factor.
The present study was undertaken to examine the feasi-
bility of RGS for APW parathyroid adenoma. Main aim of
the study was to evaluate the usefulness of this method re-
garding (a) intraoperative localization of the adenoma and
(b) control of the surgical result (cure of disease).
Case presentation
Patients
Two female patients, aged 72 (patient #1) and 79 years
(patient #2), with PHPT due to an APW parathyroidFigure 1 Aortopulmonary window parathyroid adenoma in patient #2
co-registered with 99mTc-MIBI SPECT (panels D-F) in axial (A, D), sagitadenoma were included in this study. Both patients pre-
sented with typical PHPT reflected by ionized serum cal-
cium levels of 1.73 (#1) and 1.61 mmol/L (#2), total serum
calcium levels of 3.08 (#1) and 3.04 mmol/L (#2), serum
phosphate of 0.75 (#1) and 0.64 mmol/L (#2), and elevated
parathyroid hormone (PTH) of 85.9 (#1) and 90.2 pmol/L
(#2) (normal upper value below 6.8), respectively.
Single photon emission computed tomography/X-ray
computed tomography (SPECT/CT) with 99mTc-MIBI
and contrast-enhanced computed tomography (CECT)
[21] identified ectopic parathyroid adenomas in the
APW in both patients (axial diameter 35 (#1) and
12 mm (#2), respectively) (Figure 1). Cervical ultra-
sound was negative.
Clinically, the first patient (#1) had moderate osteope-
nia but no other typical PHPT associated symptoms.
The second patient (#2), an obese type-2 diabetic with
hypertension and atrial fibrillation, presented with con-
fusion and malaise combined with dehydration and
vomiting.
Based on the imaging findings, both patients were sched-
uled for transsternal surgery without cervical exploration.
Both patients gave their informed consent for this particu-
lar clinical study.
Radioguided surgery and radioactivity measurement
At the start of surgery, 370 MBq 99mTc-MIBI were
injected intravenously. Surgery was performed using: contrast-enhanced CT (CE-CT; panels A-C) and CE-CT
tal (B, E), and coronal (C, F) orientation.
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geal nerve and intraoperative measurement of PTH.
After sternotomy, the space between the inferior margin
of the aortic arch and the left pulmonary artery was
carefully dissected. The ligament of Botalli, the left re-
current nerve and the vagus nerves were identified. 60,
90, and 120 minutes after MIBI-injection, radioactivity
was measured (in counts per second, cps) over several
areas using a gamma probe, equipped with internal
tungsten shielding and a reusable external collimated de-
tector (neo2000® GDS, Neoprobe Corp., Dublin/OH,
USA; 14 mm probe, spatial resolution 15 mm, angular
resolution 25°). As testing areas were selected: 1) the
APW, 2) the left ventricle, 3) the left thyroid lobe, 4) the
right lung, and 5) the lower abdomen. Radioactivity was
measured within an area of about 30 mm in diameter
over these regions and the mean value was used as
counted radioactivity over each region.
After removal of the adenoma (120 minutes after
MIBI-injection), the ex vivo activity of the parathyroid
adenoma was measured.
For intraoperative PTH measurement, blood samples
were taken before surgery, shortly before (pre-excision),
and 5, 10, and 20 minutes after removal of the parathy-
roid adenoma.
The removed specimens were examined histologically.
Postoperatively, blood samples for ionized and total
serum calcium and plasma PTH were taken each day
until discharge from hospital, thereafter 3 months after
surgery. Furthermore, vocal cord motility was assessed
postoperatively by direct laryngoscopy.Figure 2 Aortopulmonary window adenoma before resection (patient
brachiocephalic vein and vena cava, 2 = Brachiocephalic trunc, 3 = OpenedResults
Surgical results
In both patients, surgery was uneventful. The parathy-
roid adenomas were identified visually in the APW
within the expected position (Figure 2). In the first pa-
tient (#1), the adenoma presented as a cystic tumour of
about 35 mm in diameter; in the second patient (#2), the
adenoma was solid with a diameter of about 15 mm
(Figure 3). After removal of the adenomas (weight: 4,400
(#1) and 985 mg (#2), respectively), PTH decreased
within 10 minutes into the normal range: 89.3 (#1) and
59.2 pmol/L (#2) before excision versus 5.7 (#1) and 2.5
pmol/L (#2) ten minutes after resection.
Serum calcium and PTH were in the normal range
three months after surgery in both patients. No per-
manent recurrent nerve palsy was observed. Patient #2
showed a marked clinical improvement within a few
days after surgery.
Histological examination revealed classical parathyroid
adenoma, in the first patient (#1) with cystic degeneration.
Radioactivity measurements
The ex vivo count rate over the removed parathyroid ad-
enomas 120 minutes after MIBI-injection were 196 cps
in the cystic adenoma (#1) and 855 cps in the solid ad-
enoma (#2). Compared to these ex vivo activities, all
other counted activities were calculated as relative radio-
activity (RRA) compared to the ex vivo count rates.
The relative radioactivities 60, 90 and 120 minutes
after MIBI administration differed in all the tested re-
gions (Figure 4).#1). Aortic arch under the pledget. P = Parathyroid adenoma, 1 = Left
pericardium.
Figure 3 Removed aortopulmonary parathyroid adenomas in patient #1 (panel A) and patient #2 (B).
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tive radioactivities over the APW were above 1.5 in both
patients. No differences in counted radioactivity were
found over the APW within the tested area of about
30 mm in diameter. However, the direction of the colli-
mated gamma probe had a marked effect on the mea-
sured count rates, which were highest when the probe
was angled towards the heart. For measurement of the
RRA over the APW region, the gamma probe was there-
fore always pointed in a straight posterior direction.
After excision of the parathyroid adenoma, the relative
radioactivities in the APW decreased to 1.16 (#1) and
0.89 (#2), respectively, while relative radioactivities over
the left ventricle, about 2.5–3 cm distant from the tested
APW region, ranged between 2.0 and 5.0.
In contrast to the APW and the left heart, the relative
radioactivities over the left neck and the right lung wereFigure 4 Relative radioactivity (RAA) 60, 90, and 120 minutes
after radioactive tracer injection over different tissues in both
patients with aortopulmonary window parathyroid adenoma
(Parathyroid adenoma ex vivo RAA = 1.0).always clearly below 1.0. Over time, one patient (#1) had
slightly increasing relative radioactivities over the abdo-
men, which probably was due to tracer accumulation in
the urinary bladder as this patient was not catheterized
(Figure 4).
Discussion
In this exploratory study, we examined the feasibility of
RGS in two patients with APW parathyroid adenoma
using a transsternal approach. As expected from the
physiological tracer distribution, very high relative radio-
activities were found over the heart on all measurements
whereas the relative radioactivities over the lung and the
neck were clearly below 1.0. Within the APW, no differ-
ences in count rates were detected within an area of
30 mm in diameter, approximately twice the diameter of
the probe face. In this area, the relative radioactivities
before removal of the parathyroid adenomas were always
clearly above 1.0. Concerning intraoperative localization
(guidance) of the adenoma, however, RGS had to be
assessed as not very helpful. Removal of the parathyroid
adenoma led to a slight reduction of radioactivity within
this area in both patients. The relative radioactivities,
however, were still around 1.0, and higher when com-
pared to the relative radioactivities over the neck and
the lung.
Background activity as the key for RGS
During the last two decades, preoperative multimodality
imaging, minimal invasive parathyroidectomy, intraop-
erative PTH measurement, and RGS have had a pro-
found effect on parathyroid surgery and become routine
at many endocrine surgical centres [15,18,19]. RGS
using 99mTc-MIBI has been proposed to be particularly
useful in patients with ectopic parathyroid adenomas
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garding RGS have been reported, with injected radio-
activity ranging from 37 to 740 MBq 99mTc-MIBI.
Concerning the time interval between application and
scanning, protocols are rather similar with tracer injec-
tion around the start of surgery, which usually results in
an interval of about 30 to 90 minutes [1-4,22]. Adminis-
tration of 370 MBq is probably most common [2,4].
This protocol seems to be the best compromise regard-
ing detection accuracy and radiation protection of the
personnel.
99mTc-MIBI was originally developed for myocardial
scintigraphy [24]. The lipophilic tracer is taken up and
bound to the mitochondria of viable myocardium as well
as other hypermetabolic mitochondria-rich tissues. Thus
it is more avidly taken up by parathyroid adenomas and
hyperplastic parathyroid tissue than by normal parathy-
roid glands [9,11]. Uptake of 99mTc-MIBI is, however,
not specific to parathyroid tissue. Consequently, for de-
tection of abnormal hyperfunctioning parathyroid tissue,
different uptake kinetics between adenoma or hyperplas-
tic glands and the surrounding tissue are required. Most
of the protocols in the neck are using a 20% cut-off.
Based on that criterion, surgery is considered successful
when radioactivity of the removed specimen is more
than 20% higher than that of the surrounding (thyroid)
tissue [4,13,14].
RGS for localization of APW adenoma
This study shows that RGS for localization of APW para-
thyroid adenoma is limited by high myocardial background
activity. Due to the short distance between the heart and
the APW region, the RRA within the APW region
remained relatively high even after removal of the parathy-
roid adenoma. The count rates substantially depended on
probe direction. Therefore, in our experience, RGS is not
very helpful concerning intraoperative localization of APW
parathyroid adenomas when performing surgery via a
transsternal approach.
Some surgeons, however, prefer left thoracotomy for re-
moving APW parathyroid adenoma [19,25-28], which
might lead to an improved discrimination due to a differ-
ent position of the gamma probe. Furthermore, during the
last decade, an increasing number of reports regarding
minimal-invasive surgery of mediastinal parathyroid aden-
oma have been published [29,30]. Even though most of
these adenomas were localized in the upper and anterior
mediastinum, the feasibility of minimal-invasive surgery in
APW parathyroid adenoma using a robot-assisted ap-
proach has been demonstrated [31,32]. None of these
robot-assisted operations, however, focused on RGS.
Important enough, RGS for APW parathyroid adenoma
surgery would probably require special equipment since
the usual commercial gamma probes are not designedfor this approach. Thus, the feasibility of RGS in APW
parathyroid adenoma using robot-assisted surgery re-
mains to be demonstrated.
Testing of cure
After removal of the parathyroid adenomas, a clear RRA
reduction within the APW region was found. In addition,
the activity over the removed adenomas was much higher
when compared to other reference areas (neck, lung). On
the other hand, however, the RRA over the APW was still
around 1.0 after removal of the adenomas.
Regardless the extent of RRA decrease, decreasing
activity does not give evidence of biochemical cure at all
since other hyperfunctioning glands (e.g. in the neck)
cannot be excluded. Since intraoperative PTH measure-
ment showed normalization within 10 minutes in both
patients, no further surgery or exploration was necessary
in the two patients.
Conclusion
Lacking a clear benefit of RGS in transsternal surgery of
APW parathyroid adenoma and taken the potential side
effects (e.g. radioactive exposure of the patient and the
personnel) into consideration, RGS cannot be recom-
mended in those patients. Whether another approach or
another protocol (e.g. a longer interval between tracer
injection and measurement) would improve the results
remains to be clarified.
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